Mitchell F. Brin

23.3k citations

228 papers · 15.9k indexed · 5 hit papers · h-index 65

Impact in

Neurology top 0.02%
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Parkinson's Disease Mechanisms and Treatments
Cellular and Molecular Neuroscience top 0.1%
- Genetic Neurodegenerative Diseases
- Hereditary Neurological Disorders

Papers in

Neurology 180
- Botulinum Toxin and Related Neurological Disorders 146
- Neurological disorders and treatments 111
- Parkinson's Disease Mechanisms and Treatments 29
Cellular and Molecular Neuroscience 65
- Genetic Neurodegenerative Diseases 39
- Hereditary Neurological Disorders 29

Co-authors: Andrew Blitzer Stanley Fahn Peter G. Bain Günther Deuschl Susan Bressman Celia Stewart Laurie J. Ozelius C. Warren Olanow
Journals: Movement Disorders (27 papers)Neurology (19 papers)Medicine (11 papers)Cephalalgia (10 papers)Toxicon (10 papers)
Partner nations: United States Canada Ireland

In The Last Decade

Mitchell F. Brin

222 papers receiving 15.1k citations

Hit Papers

5 papers align trajectories log scale

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial 2011 · 343 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 European Urology
2010 Headache The Journal of Head and Face Pain
2008 Movement Disorders
2003 Annals of Neurology
1997 Nature Genetics

Peers

Countries citing papers authored by Mitchell F. Brin

Since Specialization

Citations

This map shows the geographic impact of Mitchell F. Brin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell F. Brin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell F. Brin more than expected).

Fields of papers citing papers by Mitchell F. Brin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell F. Brin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell F. Brin. The network helps show where Mitchell F. Brin may publish in the future.

Co-authors

The 25 scholars most cited alongside Mitchell F. Brin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mitchell F. Brin Line = papers co-authored together Mitchell F. Brin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Versatility of OnabotulinumtoxinA in Aesthetic Medicine Dermatologic Surgery ·Mitchell F. Brin, John Maltman, Mary Ann Chapman, Sara Sangha	2024	1
2	Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: Primary results from a randomized phase 2 study Journal of the American Academy of Dermatology ·Jean Carruthers, Steven Liew, Jason K. Rivers, Shyi-Gen Chen, Shannon Humphrey, Grace Pan, Beta Bowen, Elisabeth Lee, Mitchell F. Brin	2024	1
3	Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX®) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis Toxins ·Joseph Jankovic, Jean Carruthers, Markus Naumann, Patricia Ogilvie, Terry Boodhoo, Mayssa Attar, Swati Gupta, Ritu Singh, John Soliman, Irina Yushmanova, Mitchell F. Brin, Jie Shen	2023	16
4	Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment Neurology ·Mitchell F. Brin, Russell S. Kirby, Anne Slavotinek, Aubrey Manack Adams, Lori Parker, Ahunna Ukah, Lavinia Radulian, Monica R. P. Elmore, Larisa Yedigarova, Irina Yushmanova	2023	18
5	Early development history of Botox (onabotulinumtoxinA) Medicine ·Alan B. Scott, Dennis Honeychurch, Mitchell F. Brin	2023	12
6	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache Cephalalgia ·Edita Navratilova, Janice Oyarzo, Trent Anderson, Ron S. Broide, Sudhakar Subramaniam, Edwin Vazquez‐Cintron, Mitchell F. Brin, Todd J. Schwedt, David W. Dodick, Frank Porreca	2022	7
7	Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains Cephalalgia ·Rami Burstein, XiChun Zhang, Dan Levy, K. Roger Aoki, Mitchell F. Brin	2014	172
8	PND11 Cost of Cervical Dystonia in the United States Value in Health ·Lisa Bloudek, Mark Stacy, M. Schwartz, Mitchell F. Brin, Spyridon Papapetropoulos	2012	3
9	OnabotulinumtoxinA Treatment of Mild Glabellar Lines in Repose Dermatologic Surgery ·Alastair Carruthers, Jean Carruthers, Xiaofang Lei, Janice M. Pogoda, Nina Eadie, Mitchell F. Brin	2010	20
10	Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay Movement Disorders ·Mitchell F. Brin, Cynthia Comella, Joseph Jankovic, Francis Lai, Markus Naumann	2008	149
11	Consensus Statement of the Movement Disorder Society on Tremor Movement Disorders ·Günther Deuschl, Peter G. Bain, Mitchell F. Brin Hit paper breakdown →	2008	1227
12	Pooled Analysis of the Safety of Botulinum Toxin Type A in the Treatment of Poststroke Spasticity Archives of Physical Medicine and Rehabilitation ·Catherine C. Turkel, Beta Bowen, Jingyu Liu, Mitchell F. Brin	2006	65
13	Botulinum toxin in the clinical management of cervical dystonia Lippincott Williams & Wilkins eBooks ·Cynthia Comella, Mitchell F. Brin, Joseph Jankovic	2000	2
14	Genetic Testing for Early-Onset Torsion Dystonia ( DYT1 ): Introduction of a Simple Screening Method, Experiences from Testing of a Large Patient Cohort, and Ethical Aspects Genetic Testing ·Christine Klein, Jennifer Friedman, S. B. Bressman, P. Vieregge, Mitchell F. Brin, Peter P. Pramstaller, L De, J. Hagenah, Marcel Sieberer, Carlos Fleet, Rosemary Kiely, Weini Xin, Xandra O. Breakefield, Laurie J. Ozelius, Katherine B. Sims	1999	48
15	De Novo Mutations (GAG Deletion) in the DYT1 Gene in Two Non-Jewish Patients with Early-onset Dystonia Human Molecular Genetics ·CH Klein, Mitchell F. Brin, D. de Leon, Limborskaia Sa, I. A. Ivanova‐Smolenskaya, Susan Bressman, Alon Friedman, Elena D. Markova, Neil Risch, Xandra O. Breakefield, Laurie J. Ozelius	1998	47
16	Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients The Laryngoscope ·Andrew Blitzer, Mitchell F. Brin, Celia Stewart	1998	281
17	Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm Neurology ·Takahiro Mezaki, Ryuji Kaji, Nobuo Kohara, Haruko Fujii, M. Katayama, Tetsuya Shimizu, Jun Kimura, Mitchell F. Brin	1995	66
18	Exclusion of the DYT1 locus in a non‐Jewish family with early‐onset dystonia Movement Disorders ·Susan Bressman, Ann Hunt, Gary A. Heiman, Mitchell F. Brin, Robert E. Burke, Stanley Fahn, Joel M. Trugman, Deborah de Leon, Patricia L. Kramer, Kirk C. Wilhelmsen, Torbjoern G. Nygaard	1994	29
19	Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32–34 Annals of Neurology ·Patricia L. Kramer, Deborah de Leon, Laurie J. Ozelius, Neil Risch, Susan Bressman, Mitchell F. Brin, Deborah E. Schuback, Robert E. Burke, David J. Kwiatkowski, Heidi Shale, James F. Gusella, Xandra O. Breakefield, Stanley Fahn	1990	109
20	Analysis of the clinical course of non‐Jewish, autosomal dominant torsion dystonia Movement Disorders ·Robert E. Burke, Mitchell F. Brin, Stanley Fahn, Susan Bressman, Carol Moskowitz	1986	18

About Mitchell F. Brin

Mitchell F. Brin is a scholar working on Neurology, Cellular and Molecular Neuroscience, Psychiatry and Mental health, Physiology and Dermatology, having authored 228 papers that have together received 15.9k indexed citations. Recurring topics across this work include Botulinum Toxin and Related Neurological Disorders (146 papers), Neurological disorders and treatments (111 papers), Genetic Neurodegenerative Diseases (39 papers), Hereditary Neurological Disorders (29 papers), Migraine and Headache Studies (29 papers), Parkinson's Disease Mechanisms and Treatments (29 papers), Voice and Speech Disorders (26 papers) and Sympathectomy and Hyperhidrosis Treatments (22 papers). The work is most often cited by research in Neurology (11.3k citations), Cellular and Molecular Neuroscience (6.0k citations), Urology (1.1k citations), Psychiatry and Mental health (2.3k citations) and Physiology (3.9k citations). Mitchell F. Brin has collaborated with scholars based in United States, Canada and Ireland. Frequent co-authors include Andrew Blitzer, Stanley Fahn, Peter G. Bain, Günther Deuschl, Susan Bressman, Celia Stewart, Laurie J. Ozelius, C. Warren Olanow, Neil Risch and Robert E. Lovelace. Their work appears in journals such as Movement Disorders, Neurology, Medicine, Cephalalgia and Toxicon.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact